Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Change in Accured Expenses (2016 - 2025)

Lexaria Bioscience's Change in Accured Expenses history spans 11 years, with the latest figure at -$37613.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 95.28% year-over-year to -$37613.0; the TTM value through Nov 2025 reached $1.2 million, up 580.19%, while the annual FY2025 figure was $396637.0, 52.01% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$37613.0 at Lexaria Bioscience, down from $4787.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.5 million in Q1 2025 and bottomed at -$797423.0 in Q4 2024.
  • The 5-year median for Change in Accured Expenses is -$419.5 (2022), against an average of $67116.9.
  • The largest annual shift saw Change in Accured Expenses crashed 13829.01% in 2023 before it soared 3591.7% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $88819.0 in 2021, then rose by 1.83% to $90442.0 in 2022, then plummeted by 255.87% to -$140973.0 in 2023, then plummeted by 465.66% to -$797423.0 in 2024, then soared by 95.28% to -$37613.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Change in Accured Expenses are -$37613.0 (Q4 2025), $4787.0 (Q3 2025), and -$334819.0 (Q2 2025).